Braxia Scientific Corp, formerly Champignon Brands Inc, is a Canada-based research driven medical solutions company. The Company focuses on owning and operating multidisciplinary clinics providing treatment for mental health disorders and research activities related to discovering and commercializing drugs and delivery methods. The Company develops ketamine and psilocybin derivatives and other psychedelic products from its Internet protocol (IP) development platform. It also operates multidisciplinary community-based clinics offering treatments for depression. Its treatments include Intravenous (IV) Ketamine, Intranasal (IN) Esketamine and Oral Ketamine Tablets.
No company officers listed.
No insider trading activity.
Insider trading information report provided by Copyright © 2021. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.